{
    "2019-03-31": [
        [
            {
                "time": "",
                "original_text": "【天风医药】东阳光药：全年业绩高增长，可威动力十足品种日渐丰富",
                "features": {
                    "keywords": [
                        "东阳光药",
                        "全年业绩高增长",
                        "可威",
                        "品种日渐丰富"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "【太平洋策略-流动性周报】医药、非银迎内外资共振",
                "features": {
                    "keywords": [
                        "医药",
                        "非银",
                        "内外资共振"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "非银"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "创新疫苗将进入第二波浪潮，重新梳理长期医药十年十倍四大主线【国盛医药张金洋团队】",
                "features": {
                    "keywords": [
                        "创新疫苗",
                        "第二波浪潮",
                        "医药十年十倍",
                        "四大主线"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "4+7落地深度追踪：联动态度不一、原研仍存机会",
                "features": {
                    "keywords": [
                        "4+7落地",
                        "联动态度不一",
                        "原研仍存机会"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "西南证券：心有猛虎 细嗅蔷薇",
                "features": {
                    "keywords": [
                        "西南证券",
                        "心有猛虎",
                        "细嗅蔷薇"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "恒瑞市值涨超400亿 11家药企跌出500强",
                "features": {
                    "keywords": [
                        "恒瑞",
                        "市值涨超400亿",
                        "药企跌出500强"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "mixed",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "mixed"
                }
            },
            {
                "time": "",
                "original_text": "一季度基金回报喜人！最高斩获56%收益 冠军基金经理看好这两大板块",
                "features": {
                    "keywords": [
                        "一季度基金回报",
                        "56%收益",
                        "冠军基金经理",
                        "两大板块"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "聚焦一季报行情，关注“创新+升级” | 【光大医药·周报】",
                "features": {
                    "keywords": [
                        "一季报行情",
                        "创新+升级",
                        "光大医药"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}